Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b double-blind trial of PF-00610355 versus salmeterol and placebo in COPD
2008-005249-51Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PF-00610355 in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by Pfizer. Primary endpoint: Change from baseline in trough FEV1 at Week 6. Started Jan 2009; status: completed.
02
Drugs
PF-00610355
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2008-005249-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005249-51.